UNSPSC 51422301: Alclometasone

This classification denotes a therapeutic glucocorticoid, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier 136H45TB7B. European Medicines Agency schedules Alclometasone in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB05300MIG. Alclometasone generally arises in the molecular formula C22H29CLO5.

UNSPSC 51422301 Alclometasone, a Commodity code, nominally describes a specific corticosteroid topical medication; however, the recent state and local opportunities tagged under this code show little alignment with that narrow pharmaceutical product scope. The two recent opportunities on record involve naloxone procurement (an opioid antagonist unrelated to alclometasone) and a broader exploratory request for information on direct-to-manufacturer prescription programs. State and local buyers soliciting under this code appear limited in volume and geographically dispersed, with no pattern of repeat activity or concentrated demand visible in the recent record.

Seminole County, Florida issued an Invitation for Bid (IFB 60459723LAS) on June 30, 2026, for 1,900 units of Naloxone and 800 Safe Drug Deactivation Systems annually, with quarterly deliveries to the Seminole County Community Health Building and a response deadline of July 26, 2023. The Texas Health and Human Services Commission posted a Request for Information (RFI HHS0017013) on April 3, 2026, to solicit vendor capabilities regarding a Therapeutic Pharmacy Initiative Direct-to-Manufacturer Prescriptions program, seeking information on direct contracting models and prescription fulfillment strategies without a formal response deadline or award value. The mismatch between the code's nominal scope (a single topical steroid) and the actual opportunities (naloxone, opioid-antagonist systems, and broad pharmaceutical distribution models) suggests that the code assignment may not reflect current state and local procurement practice, or that the code sees limited relevant activity. No established pattern of geographic concentration or issuing-body repeat buyers emerges from the available record.